Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interindividual variability in metformin pharmacokinetics in pediatric patients.

Pediatric research·2026
Same author

Severe Thiopurine-Induced Myelosuppression in a Pediatric Acute Lymphoblastic Leukemia Patient With the NUDT15 *1/*6 Genotype: A Brief Report.

Clinical and translational science·2026
Same author

PharmVar GeneFocus: CYP1A2-Clinical Impact, Genetic Variation, and Updated Nomenclature.

Clinical pharmacology and therapeutics·2026
Same author

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5-HT<sub>3</sub> Receptor Antagonists: 2026 Update.

Clinical pharmacology and therapeutics·2026
Same author

Impact of CYP2D6 Metabolizer Status on Ondansetron Efficacy in Early Pregnancy Induced Nausea and Vomiting: A Case Control Study.

Clinical and translational science·2026
Same author

PharmVar GeneFocus: NAT2-Genetic Variation and Updated Nomenclature.

Clinical pharmacology and therapeutics·2025

Related Experiment Video

Updated: Oct 4, 2025

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.1K

CYP2C8, CYP2C9, and CYP2C19 Characterization Using Next-Generation Sequencing and Haplotype Analysis: A GeT-RM

Andrea Gaedigk1, Erin C Boone2, Steven E Scherer3

  • 1Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, Missouri; University of Missouri-Kansas City School of Medicine, Kansas City, Missouri.

The Journal of Molecular Diagnostics : JMD
|February 8, 2022
PubMed
Summary
This summary is machine-generated.

Next-generation sequencing (NGS) identified novel pharmacogenetic alleles missed by targeted tests. This advanced sequencing improves accuracy in predicting drug response and patient care by uncovering previously unknown genetic variations.

More Related Videos

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.3K
qPCRTag Analysis - A High Throughput, Real Time PCR Assay for Sc2.0 Genotyping
07:00

qPCRTag Analysis - A High Throughput, Real Time PCR Assay for Sc2.0 Genotyping

Published on: May 25, 2015

17.3K

Related Experiment Videos

Last Updated: Oct 4, 2025

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.1K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.3K
qPCRTag Analysis - A High Throughput, Real Time PCR Assay for Sc2.0 Genotyping
07:00

qPCRTag Analysis - A High Throughput, Real Time PCR Assay for Sc2.0 Genotyping

Published on: May 25, 2015

17.3K

Area of Science:

  • Pharmacogenomics
  • Genetics
  • Molecular Biology

Background:

  • Targeted genotyping assays for pharmacogenetics often use star (*) allele nomenclature.
  • These assays may miss novel variants, impacting phenotype prediction and patient care.

Purpose of the Study:

  • To recharacterize DNA samples using targeted and whole genome sequencing.
  • To identify novel alleles and resolve ambiguous genotype calls in CYP2C8, CYP2C9, and CYP2C19.

Main Methods:

  • Utilized targeted and whole genome sequencing on 137 DNA samples previously characterized by GeT-RM.
  • Applied three genotype calling tools to analyze sequence data for star allele diplotypes.
  • Employed next-generation sequencing (NGS) and long-read NGS data.

Main Results:

  • NGS correlated well with previous genotype calls, except when novel alleles were present.
  • Identified six novel alleles and 38 novel suballeles across CYP2C8, CYP2C9, and CYP2C19.
  • Resolved several ambiguous genotype calls using NGS data.

Conclusions:

  • NGS is highly valuable for pharmacogenetic testing, revealing numerous novel alleles.
  • Even well-studied genes like CYP2C9 and CYP2C19 harbor undiscovered variants.
  • Advanced sequencing methods enhance the precision of pharmacogenetic diagnostics.